You are here

Clinical Trials

WHAT ARE CLINICAL TRIALS?

Clinical trials are research studies that are designed to answer scientific questions and find better ways to prevent, diagnose or treat various diseases and conditions, including cancer. A clinical trial is one of the final stages of a long and careful cancer research process. The search for new treatments begins in the laboratory, where scientists first develop and test new ideas. If an approach seems promising, the next step may be testing a treatment in animals, to see how it affects cancer in a living being, and whether it has harmful effects. However, treatments that work well in the lab or in animals do not always work well in people. When the potential treatment is deemed safe enough to explore their effects on humans, it proceeds to be studied in a clinical trial. In the context of cancer, these trials are done with cancer patients to find out whether promising treatments are safe and effective.

The most successful cancer treatments that we have today are based on what we have learned from clinical trials. As a result, people with cancer are living longer, with a better quality of life. Participating in clinical trials at the University of Illinois Cancer Center may benefit you, but also helps to develop newer, safer treatments for future cancer patients.

For more information about cancer clinical trials, please see the following resources: National Cancer Institute (NCI), Clinical Trials Information for Patients and Caregivers, The American Cancer Society, Clinical Trials, Cancer Support Community, Cancer Clinical Trials, ClinicalTrials.gov clinical trials database

Below is a listing of UI Cancer Center clinical studies currently enrolling participants.  Click on the dropdown menu below to filter the list by the site of your disease.  If you are interested in participating in a trial listed, please email cancertrials@uic.edu or call 312-355-5112.

For more information on the study, click on the ClinicalTrials.gov ID, if available.
For a list of clinical trials nationwide, please see www.ClinicalTrials.gov.

Study Title Researcher Adult/Children Sponsor Disease Site ClinicalTrials.gov ID
SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER/NEU Negative Breast CancerDanciu, Oana, CAdultsSouthwest Oncology GroupBreast - Female; Breast - Male NCT01674140
RU011201I: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First or Second-line Therapy for Locally Recurrent or Metastatic Breast CancerDanciu, Oana, CAdultsACCRU- IndustryBreast - Female NCT02037529
NSABP B-55: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Danciu, Oana, CAdultsNational Surgical Adjuvant Breast and Bowel ProjectBreast - Female; Breast - Male NCT02032823
STM-03: Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid TumorsDanciu, Oana, CAdultsVanquish Oncology, Inc.Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kidney; Larynx; Leukemia, not otherwise specified; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid NCT02355535
BTCRC-BRE15-016: A Single Arm Phase II Study OF Palbociclib In Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast CancerDanciu, Oana, CAdultsBig Ten Cancer Research ConsortiumBreast - Female NCT02668666
EMR200647-001- A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansionDanciu, Oana, CAdultsEMD Serono, Inc.Brain and Nervous System; Breast - Female; Breast - Male; Colon; Kaposi's sarcoma; Larynx; Lip, Oral Cavity and Pharynx; Melanoma, skin; Multiple Myeloma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Urinary; Ovary; Soft Tissue NCT02517398
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerDanciu, Oana, CAdultsNRG OncologyBreast - Female NCT02488967
A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC TrialDanciu, Oana, CAdultsAllianceBreast - Female NCT02927249
S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After NeoadjuDanciu, Oana, CAdultsSouthwest Oncology GroupBreast - Female NCT02954874
GO29527: A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (ANTI−PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients witFeldman, LawrenceAdultsGenentechLung NCT02486718
BTCRC-LUN15-017: Phase II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Non-small Cell Lung Cancer Who Progressed after First Line ChemotherapyFeldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03003468
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029Feldman, LawrenceAdultsBig Ten Cancer Research ConsortiumLung NCT03083808
Feasibility and Acceptability of a Fertility Preservation Decision Support Aid for Young Women with Cancer: An Intervention Development Pilot StudyHershberger, PatriciaAdultsUniversity of Illinois at Chicago (UIC)Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's sarcoma; Kidney; Larynx; Leukemia, not otherwise specified; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomac
Lean Body Mass Calculation of Cancer Survivors at UI HealthHong, SusanAdultsAnus; Bladder; Breast - Female; Cervix Uteri; Colon; Lung; Other Female Genital; Other Male Genital; Other Urinary; Ovary; Prostate; Rectum
Screening Mammogram Family History RegistryHong, SusanAdultsBreast - Female; Breast - Male; Ovary
NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerHoskins, KentAdultsNRG OncologyBreast - Female; Breast - Male NCT02364557
PALLAS (AFT-05): Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/HER2-negative Early Breast CancerHoskins, KentAdultsAlliance Foundation Trials (AFT)Breast - Female; Breast - Male NCT02513394
Creating a Culturally-Tailored Intervention to Improve Uptake of Genetic Counseling Among Underserved African American Women with Increased Breast Cancer RiskHoskins, KentAdultsNational Cancer InstituteBreast - Female
NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to PathologicalHoskins, KentAdultsNational Surgical Adjuvant Breast and Bowel ProjectBreast - Female NCT01872975
MK-3475-355 - A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)Hoskins, KentAdultsMerck, Sharpe & Dohme Corp.Breast - Female NCT02819518
BTCRC-BRE15-024: A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination w/Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast CancerHoskins, KentAdultsBig Ten Cancer Research Consortium NCT03090165
The Use of Myofascial Release to Augment Dysphagia Therapy Success in Post-Treatment Head and Neck Cancer Patients.Jefferson, GinaAdultsUniversity of Illinois at Chicago (UIC)Lip, Oral Cavity and Pharynx
OncoNova 04-30: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome After Failure of a Hypomethylating AgentKhan, IrumAdultsOnconovaMyeloid and Monocytic Leukemia NCT02562443
Effects of Stellate Ganglion Block on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast CancerMaki, PaulineAdultsNorthwestern UniversityBreast - Female NCT02513329
A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell SubtypePatel, Pritesh, RAdultsAllianceNon-Hodgkin's Lymphoma NCT02443077
E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in AdultsQuigley, John (Sean)AdultsEastern Cooperative Oncology GroupLymphoid Leukemia NCT02003222
AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML patientsQuigley, John (Sean)AdultsTeva Branded Pharmaceutical Products R&DMyeloid and Monocytic Leukemia NCT02440568
BMT CTN 07LT: Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702Rondelli, DamianoAdultsBMT CTNMultiple Myeloma NCT02322320
BMT-05: A Phase II Study of Intensity Modulated Total Marrow Irradiation (TMI) in Addition to Fludarabine/ Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesRondelli, DamianoAdultsUniversity of Illinois at Chicago (UIC)Leukemia, not otherwise specified; Leukemia, other; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma NCT03121014
GRAVITAS-301: A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus Host DiseaseRondelli, DamianoAdultsIncyte CorporationOther Hematopoietic NCT03139604
ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET PatientsSchmidt, Mary LouBothChildren's Oncology GroupBrain and Nervous System NCT00392327
ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in patients with Newly Diagnosed Ependymoma Ages 1 to 21 yearsSchmidt, Mary LouBothChildren's Oncology GroupBrain and Nervous System NCT01096368
AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC#606869) in the Very High Risk StratumSchmidt, Mary LouBothChildren's Oncology GroupLeukemia, other; Lymphoid Leukemia NCT01406756
ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALLSchmidt, Mary LouBothChildren's Oncology GroupLeukemia, other; Lymphoid Leukemia NCT01503632
ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)Schmidt, Mary LouBothChildren's Oncology GroupBrain and Nervous System NCT01602666
ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117Schmidt, Mary LouBothChildren's Oncology GroupNon-Hodgkin's Lymphoma NCT01979536
AHEP0731: Treatment of Children with All Stages of HepatoblastomaSchmidt, Mary LouBothChildren's Oncology GroupLiver NCT00980460
ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)Schmidt, Mary LouBothChildren's Oncology GroupBones and Joints; Other Skin; Soft Tissue NCT02180867
AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)Schmidt, Mary LouBothChildren's Oncology GroupLymphoid Leukemia NCT02112916
ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaSchmidt, Mary LouChildrenChildren's Oncology GroupBrain and Nervous System NCT02176967
AALL1331:Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Schmidt, Mary LouBothChildren's Oncology GroupLymphoid Leukemia NCT02101853
AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaSchmidt, Mary LouBothChildren's Oncology GroupSoft Tissue NCT02306161
AHOD1331, A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and AdolescentsSchmidt, Mary LouBothChildren's Oncology GroupHodgkin's Lymphoma NCT02166463
AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic AcidSchmidt, Mary LouBothChildren's Oncology GroupLeukemia, other NCT02339740
AOST1321: Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory OsteosarcomaSchmidt, Mary LouBothChildren's Oncology GroupBones and Joints NCT02470091
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeSchmidt, Mary LouChildrenChildren's Oncology GroupLeukemia, other NCT02521493
AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene RearrangementSchmidt, Mary LouChildrenChildren's Oncology GroupLeukemia, other; Lymphoid Leukemia NCT02828358
ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsSchmidt, Mary LouBothChildren's Oncology GroupBrain and Nervous System; Eye and Orbit NCT02724579
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)Schmidt, Mary LouBothChildren's Oncology GroupLymphoid Leukemia NCT02981628
Investigational Oocyte cryopreservation for medical and non medical indicationsScoccia, HumbertoAdultsUniversity of Illinois at Chicago (UIC)Ovary
BMT-07: Pilot Study to Determine Target Melphalan Exposure in Patients with Multiple Myeloma Undergoing Autologous Stem Cell TransplantationSweiss, KarenAdultsUniversity of Illinois at Chicago (UIC)
Obesity, Iron Regulation, and Colorectal Cancer RiskTussing-Humphreys, LisaAdultsAmerican Cancer SocietyColon
Diet modulation of bacterial sulfur & bile acid metabolism and colon cancer riskTussing-Humphreys, LisaAdultsNational Cancer InstituteColon
NCCTG N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with ToVenepalli, Neeta, KAdultsNorth Central Cancer Treatment GroupRectum NCT01515787
RTOG 1112: Randomized Phase III Study of Sorafenib Versus Sterotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaVenepalli, Neeta, KAdultsRadiation Therapy Oncology GroupLiver NCT01730937
BTCRC-GI13-002: An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular CarcinomaVenepalli, Neeta, KAdultsBig Ten Cancer Research ConsortiumLiver NCT02575339